Hyderabad-based Dr. Reddy's Laboratories is embarking on a significant strategic shift, moving beyond its traditional reliance on US generics, particularly the cancer drug Lenalidomide. The pharmaceutical giant is now directing its investments and future growth expectations towards high-potential areas such as obesity therapies, biosimilars, and consumer healthcare.
Strategic Pivot Driven by Market Pressures
The company's latest financial performance highlights the increasing pressure on its North American generics business. Revenues from the region saw a substantial decline of 51% year-on-year in the March quarter, falling to ₹1,756 crore, and a 22% drop for the full year to ₹11,374 crore. This downturn is primarily attributed to lower Lenalidomide sales and a one-time shelf stock adjustment related to the product.
In contrast, Dr. Reddy's branded businesses in India and Europe demonstrated robust growth. India revenues increased by 20% year-on-year in the March quarter and 16% for the full year, bolstered by new product launches, price adjustments, higher volumes, and acquired portfolios. Europe also contributed significantly, with revenues rising 55% year-on-year in FY26 to ₹5,550 crore, partly due to the integration of a nicotine replacement therapy portfolio.
Investing in New Growth Avenues
A key focus for Dr. Reddy's is the rapidly expanding market for metabolic disease treatments. The company recently launched generic Semaglutide injection in India under the brand name Obeda, following the loss of exclusivity for the original drug. It also secured marketing authorization from the Drugs Controller General of India for generic Semaglutide tablets, a widely used compound for diabetes and obesity management globally.
Beyond obesity drugs, Dr. Reddy's is expanding its footprint in biosimilars and specialty products. The US Food and Drug Administration (FDA) has accepted for review the biologics license application for the intravenous presentation of Dr. Reddy’s abatacept biosimilar in the United States, marking a significant step in this segment.
The consumer healthcare division is also becoming an increasingly vital part of the company's portfolio. Dr. Reddy's reported the near-completion (95%) of the integration of its acquired nicotine replacement therapy business by March 2026, contributing to its strong performance in Europe.
Financial Performance and Future Outlook
For the full financial year 2026, Dr. Reddy’s reported consolidated revenue growth of 3.2% to ₹33,593 crore. However, profit after tax saw a decline of 24% to ₹4,285 crore, reflecting the impact of the North American challenges and other one-off events.
“Our performance this year reflects the impact of lower Lenalidomide sales and several one-offs. The resilience of our branded businesses and currency tailwinds helped partially mitigate this impact,” stated G V Prasad, Co-Chairman and Managing Director of Dr. Reddy’s. He further emphasized the company’s commitment to “improving margins through cost efficiencies and portfolio optimisation while continuing investments in biosimilars, consumer health and innovation.”
As part of its portfolio rationalization, the company has become more selective in its innovation pipeline, discontinuing certain CAR-T therapy programs during the quarter and incurring related impairment charges. R&D spending for FY26 decreased by 12% year-on-year to ₹2,406 crore, partly due to reduced development spending in biosimilars after significant investments in abatacept were completed.